Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Latency-Associated Nuclear Antigen (LANA)

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_7209-1

Synonyms

Definition

The latency-associated nuclear antigen (LANA) is one of the major latent proteins of the Kaposi’s sarcoma herpesvirus (KSHV) or human herpesvirus 8 (HHV8). It was first discovered as a serologic antigen, and since then it is a gold standard detection tool for KSHV infection. KSHV is associated with Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), and Multicentric Castleman disease (MCD), and LANA is detected in any form of KS. In KSHV-infected cells LANA is detected as a dot-like staining by immunohistochemistry or immunofluorescence.

Characteristics

Structure

LANA is encoded by KSHV ORF73, and it is mainly expressed from a polycistronic transcript (LT1). LT1 also includes other latent proteins as v-cyclin, a viral homologue of the cellular cyclin D, and the viral homologue of the cellular FLICE-like inhibitory protein (v-FLIP). These last two proteins encoded by ORF72 and ORF71/K13,...

Keywords

Origin Recognition Complex Primary Effusion Lymphoma Lytic Replication Multicentric Castleman Disease Major Latent Promoter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Campbell M, Kung HJ, Izumiya Y (2014) Long non-coding RNA and epigenetic gene regulation of KSHV. Viruses 6:4165–4177PubMedCentralCrossRefPubMedGoogle Scholar
  2. Cousins E, Nicholas J (2014) Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication. Recent Results Cancer Res 193:227–268PubMedCentralCrossRefPubMedGoogle Scholar
  3. Dittmer DP, Damania B (2013) Kaposi sarcoma associated herpesvirus pathogenesis (KSHV) – an update. Curr Opin Virol 3:238–244PubMedCentralCrossRefPubMedGoogle Scholar
  4. Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, Phair J, Detels R, Parry P, Chang Y, Moore PS (1996) Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med 335:233–241CrossRefPubMedGoogle Scholar
  5. Lieberman PM (2013) Keeping it quiet: chromatin control of gammaherpesvirus latency. Nat Rev Microbiol 11:863–875PubMedCentralCrossRefPubMedGoogle Scholar
  6. Moore PS (2007) KSHV manipulation of the cell cycle and apoptosis. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (eds) Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, Chapter 30Google Scholar
  7. Rainbow L, Platt GM, Simpson GR, Sarid R, Gao SJ, Stoiber H, Herrington CS, Moore PS, Schulz TF (1997) The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virol 71:5915–5921PubMedCentralPubMedGoogle Scholar
  8. Uppal T, Banerjee S, Sun Z, Verma SC, Robertson ES (2014) KSHV LANA-the master regulator of KSHV latency. Viruses 6:4961–4998PubMedCentralCrossRefPubMedGoogle Scholar

See Also

  1. (2012) p53. In Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2747. doi:10.1007/978-3-642-16483-5_4331Google Scholar
  2. (2012) pRb. In Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2967. doi:10.1007/978-3-642-16483-5_4708Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Molecular Microbiology and Immunology, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA